

## WHO-PQ RECOMMENDED SUMMARY OF PRODUCT CHARACTERISTICS

*This summary of product characteristics focuses on uses of the medicine covered by WHO's Prequalification Team - Medicines. The recommendations for use are based on WHO guidelines and on information from stringent regulatory authorities.\**

*The medicine may be authorised for additional or different uses by national medicines regulatory authorities.*

---

\*[https://extranet.who.int/pqweb/sites/default/files/documents/75%20SRA%20clarification\\_Feb2017\\_newtempl.pdf](https://extranet.who.int/pqweb/sites/default/files/documents/75%20SRA%20clarification_Feb2017_newtempl.pdf)

## 1. NAME OF THE MEDICINAL PRODUCT

[TB183 trade name]†

## 2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each film coated tablet contains:

Ethambutol hydrochloride 275 mg, isoniazid 75 mg and rifampicin 150 mg

[TB183 trade name] contains a colorant (Color Ponceau 4R aluminium Lake) which may cause allergic reactions.

For the full list of excipients see section 6.1.

## 3. PHARMACEUTICAL FORM

Maroon coloured, circular, biconvex, film-coated tablets having plain surface on both the sides. The tablet should not be divided.

## 4. CLINICAL PARTICULARS

### 4.1 Therapeutic indications

[TB183 trade name] is a combination medicine for the initial treatment of tuberculosis due to *Mycobacterium tuberculosis*.

Treatment regimens should follow the most recent WHO treatment guidelines, supplemented by other authoritative guidelines.

### 4.2 Posology and method of administration

For oral use.

#### *Posology*

Treatment regimens should follow the most recent WHO treatment guidelines, supplemented by other authoritative guidelines.

Initial (intensive phase) treatment with [TB183 trade name] is normally given for 2 months in combination with pyrazinamide, which is generally followed by treatment with isoniazid and rifampicin (continuation phase). The duration of treatment depends on the regimen selected.

Typical recommended doses of [TB183 trade name] for initial (intensive phase) treatment in adults and children weighing more than 25 kg:

Patients' weight	Dose
25–29.9 kg	2 tablets once daily
30–34.9 kg	3 tablets once daily
35–64.9 kg	4 tablets once daily
65 kg and over	5 tablets once daily

[TB183 trade name] should not be used for intermittent treatment regimens.

[TB183 trade name] should be taken as a single daily dose on an empty stomach (at least 1 hour before or 2 hours after a meal). Absorption may be reduced if taken with food e.g. to improve gastrointestinal tolerance.

---

† Trade names are not prequalified by WHO. This is the national medicines regulatory agency's responsibility.

If one of the active ingredients of this medicine needs to be discontinued or if the dose needs to be reduced then separate preparations of the ingredients (ethambutol, isoniazid and rifampicin) should be used.

Supplementation with pyridoxine (vitamin B<sub>6</sub>) may be considered, especially in malnourished individuals, children and those living with HIV (see section 4.4).

#### *Renal impairment*

Since dose adjustment may be necessary in patients with renal impairment (creatinine clearance  $\leq 50$  mL/minute), it is recommended that separate preparations of ethambutol, isoniazid, pyrazinamide, and rifampicin be used (see section 4.3 and 4.4).

#### *Hepatic impairment*

Limited data indicate that the pharmacokinetics of isoniazid and rifampicin are altered in patients with hepatic impairment. Therefore, patients with hepatic impairment should be closely observed for signs of toxicity. [TB183 trade name] must not be used in patients with a history of acute liver disease (see section 4.3).

#### *Children, adolescents and patients weighing less than 25 kg*

[TB183 trade name] is not suitable for patients with a body weight below 25 kg, since appropriate dose adjustments cannot be made. Alternative formulations should be used.

#### *Elderly*

No special dosage regimen is necessary, but hepatic or renal insufficiency should be considered. Supplementation of pyridoxine (vitamin B<sub>6</sub>) may be useful.

#### ***Interruption of treatment***

If treatment with [TB183 trade name] is interrupted for any reason including non-adherence, the product should **not** be used for resuming treatment. Ethambutol, isoniazid and rifampicin must be administered separately for the resumption of treatment because rifampicin needs to be reintroduced at a lower dose. Official guidance should be consulted on the resumption of treatment with tuberculosis medicines.

#### *Missed dose and vomiting after a dose*

It is important that the patient takes the medicine regularly as prescribed. Missing doses can increase the risk of resistance to [TB183 trade name] and reduce its effectiveness.

If the patient misses a dose and it is less than 12 hours after it was due, the patient should be advised to take the dose as soon as possible and then take the next dose at the scheduled time. If more than 12 hours have passed since the dose was due, the patient should omit the missed dose and take the next scheduled dose at the usual time. The patient should not take a double dose.

If the patient vomits within 1 hour of taking [TB183 trade name], the patient should take an extra dose. If vomiting occurs more than an hour after taking the dose, the patient does not need to take an extra dose and can take the next dose as usual when it is due.

### **4.3 Contraindications**

Hypersensitivity to rifamycins, isoniazid, ethambutol and/or any of the excipients listed in section 6.1..

A history of acute liver disease, icterus or severe liver impairment, regardless of its origin.

Renal impairment requiring dose adjustment (see section 4.4).

Concomitant use with voriconazole or protease inhibitors for HIV or hepatitis C infection (see section 4.5).

#### 4.4 Special warnings and precautions for use

##### **Warnings**

Where the patient's acetylation phenotype is known, patients with extremely fast or extremely slow acetylating capability should receive the four components separately in order to facilitate dose adjustment of isoniazid.

[TB183 trade name] is not suitable for use in the treatment of patients with a body weight of less than 25 kg, since appropriate dose adjustments cannot be made. Other formulations should be used that allow suitable doses to be given .

##### *Hypersensitivity*

In exceptional cases, **rifampicin** may provoke severe hypersensitivity reactions such as thrombocytopenia, purpura, haemolytic anaemia, dyspnoea and asthma-like attacks, shock or renal failure. [TB183 trade name] should be withdrawn immediately if severe acute hypersensitivity reactions occur. Patients who develop such reactions must never again be treated with rifampicin.

[TB183 trade name] should also be withdrawn if other signs of hypersensitivity appear, such as fever, flu-like symptoms or skin reactions. For safety reasons, treatment should not be continued or resumed with rifampicin.

The risk is higher in intermittent therapy or if treatment is resumed after discontinuation. If rifampicin therapy is temporarily discontinued for other reasons, rifampicin should be restarted carefully at a reduced dose, and with close monitoring. In this situation, [TB183 trade name] should not be used.

*Cross-sensitivity:* Patients hypersensitive to ethionamide, niacin (nicotinic acid), or other chemically related medications may also be hypersensitive to isoniazid.

##### *Visual acuity*

Because ethambutol may cause ocular toxicity, patients should be advised to report promptly any changes in visual acuity. Therapy with [TB183 trade name] must be discontinued immediately if visual disturbances emerge (see section 4.8).

[TB183 trade name] should be used with care in patients with visual defects and avoided in patients with pre-existing optic neuritis. An ophthalmic examination is recommended before starting treatment and every 4 weeks during treatment. It should include visual acuity, colour vision, field of vision and ophthalmoscopy. For patients with visual defects or renal insufficiency the frequency of tests should be increased to every second or third week.

Patients who cannot report changes to their visual acuity should be more closely monitored for any deterioration during treatment with ethambutol. In young children and those with communication difficulties, parents or other family members should be given advice about the need to report visual side effects.

##### **Precautions**

The precautions for the use of [TB183 trade name] are the same as those that apply for the administration of rifampicin, isoniazid, and ethambutol as individual medicinal products.

Patients should be advised against interrupting treatment except as indicated by their health care provider (e.g. pending clinical evaluation if visual disturbances occur).

##### *Liver toxicity*

Rifampicin, isoniazid and ethambutol are metabolised in the liver. Elevated transaminase levels, above the upper limit of normal (ULN), commonly occur. Liver dysfunction that may occur in the first few weeks of treatment usually returns to the normal range spontaneously, without interruption of treatment, and usually by the third month of treatment.

With rifampicin, although slight elevations of liver enzymes are common, clinical jaundice or evidence of hepatitis are rare. In patients taking both isoniazid and rifampicin, a cholestatic pattern with elevated

alkaline phosphatase suggests that rifampicin is the causative agent, whereas a rise in transaminases may be caused by isoniazid or rifampicin, or the combination of both.

A moderate rise in bilirubin and/or transaminase levels is not in itself an indication for interrupting treatment; rather, the decision should be made after repeating these liver function tests, noting trends in the levels, and considering them in conjunction with the patient's clinical condition.

Interrupting isoniazid treatment is recommended when there is clinical jaundice or transaminases exceed 3 times the ULN. The fixed drug combination, [TB183 trade name], should be replaced by individual component formulations of rifampicin, isoniazid and ethambutol in order to facilitate treatment in these clinical circumstances.

Withdrawing rifampicin, pyrazinamide and ethambutol is recommended if liver function does not return to normal or transaminases exceed 5 times the ULN. The fixed drug combination, [TB183 trade name], should be replaced by individual component formulations in order to facilitate treatment in these clinical circumstances.

Patients with impaired liver function should be treated with caution and under strict medical supervision.

In these patients, careful monitoring of liver function, especially serum glutamic pyruvic transaminase (SGPT/ALAT) and serum glutamic oxaloacetic transaminase (SGOT/ASAT) should be carried out prior to therapy and repeated weekly or fortnightly during therapy. If signs of hepatocellular damage occur, [TB183 trade name] should be withdrawn.

In general, use of [TB183 trade name] in patients with a history of acute liver disease is contra-indicated (see section 4.3). Use of isoniazid should be carefully monitored in patients with chronic liver disease. Severe and sometimes fatal hepatitis caused by isoniazid may occur and may develop even after many months of treatment. Hepatotoxicity associated with isoniazid therapy (thought to be caused by the metabolite diacetylhydrazine) is rare in patients up to 20 years of age, but more common with increasing age and affects up to 3% of patients aged over 50 years. The incidence of severe hepatotoxicity can be minimised by careful monitoring of liver function. All patients should be instructed to immediately report signs or symptoms consistent with liver damage or other adverse effects. These include any of the following: unexplained anorexia, nausea, vomiting, dark urine, icterus, rash, persistent paraesthesias of the hands and feet, persistent fatigue and/or weakness of greater than 3 days duration and/or abdominal tenderness, especially of the right upper quadrant. If these symptoms appear or if signs suggestive of hepatic damage are detected, [TB183 trade name] should be discontinued promptly, since continued use in these cases may cause a more severe form of liver damage.

[TB183 trade name] is not suitable for use in patients with chronic liver disease, or in chronic alcoholics and undernourished patients, if the dosage of rifampicin, isoniazid, pyrazinamide and ethambutol needs to be adjusted separately.

For undernourished or elderly patients supplementation of pyridoxine (vitamin B6) may be useful, because isoniazid in high doses can lead to pyridoxine (vitamin B6) deficiency. Pyridoxine supplementation is also recommended in malnourished children and adolescents, in those who are pregnant or breastfeeding, and those living with HIV, at a dosage of 0.5–1 mg/kg daily, increased to 2–5 mg/kg daily if peripheral neuropathy develops.

#### *Peripheral neuropathy*

This is a common toxic effect of isoniazid (see section 4.8). The frequency depends on the dose and on predisposing conditions such as malnutrition, alcoholism or diabetes. Use of pyridoxine (vitamin B6) may prevent or diminish neuropathy due to isoniazid treatment especially in elderly and in malnourished patients, and patients living with HIV. Pyridoxine should be given in line with official guidelines.

#### *Epilepsy*

Patients suffering from convulsive disorders must be kept under special observation during treatment with [TB183 trade name] because of the neurotoxic effects of isoniazid and ethambutol hydrochloride.

### *Haematological toxicity*

Since rifampicin treatment has been associated with haemolytic anaemia, leukopenia and thrombocytopenia, full blood count should be monitored regularly throughout therapy with [TB183 trade name]. In case of severe haematological disturbances [TB183 trade name] should be discontinued and the patient should not be given rifampicin again.

### *Hyperuricaemia and gout*

Ethambutol is excreted via the same pathway as uric acid, thereby leading to increased serum concentration of uric acid. Concomitant therapy with isoniazid or pyridoxine may enhance this effect. Patients with pre-existing hyperuricaemia or symptoms of gout should be monitored for signs of deterioration when treated with ethambutol (see sections 4.5 and 4.8).

### *Renal insufficiency*

In renal insufficiency, the clearance of ethambutol and isoniazid is delayed, causing an increased systemic exposure. In case of renal insufficiency, [TB183 trade name] should not be used, as dose modifications of the active components may be necessary (see section 4.2)

### *Nephrotoxicity*

[TB183 trade name] should be discontinued in case of clinical signs of nephrotoxicity.

### *Diabetes mellitus*

Patients with diabetes should be carefully monitored, since blood glucose control may be affected by isoniazid.

### *Concomitant medications*

Rifampicin is a potent inducer of the cytochrome P450 system, and may increase the metabolism of concomitantly administered drugs resulting in subtherapeutic plasma levels and a lack of effect. Drugs that are eliminated by hepatic metabolism should only be used concomitantly with [TB183 trade name] if the plasma level or clinical response / undesirable effects can be monitored and the dose can be adequately adjusted (see section 4.5).

Rifampicin has enzyme induction properties that can enhance the metabolism of endogenous substrates including adrenal corticosteroids, thyroid hormones and vitamin D.

### *Contraception*

Additional non-hormonal means of contraception must be employed to prevent the possibility of pregnancy during treatment with rifampicin (see section 4.5).

### *Alcohol*

The intake of alcoholic beverages should be avoided during treatment with [TB183 trade name] (see section 4.5).

### *Porphyria*

Isolated reports have associated porphyria exacerbation with rifampicin administration.

### *Discoloration of body fluids*

[TB183 trade name] may cause a reddish-orange discoloration of body fluids such as urine, sputum and tears. This is due to rifampicin, and does not require medical attention.

### *Laboratory tests*

Full blood counts, liver function tests (SGPT/ALAT, SGOT/ASAT), renal function tests and monitoring serum uric acid should be performed before treatment and at regular intervals during treatment. Ocular examination is recommended during treatment with ethambutol hydrochloride.

### *Excipients*

[TB183 trade name] contains a colorant (Color Ponceau 4R aluminium Lake) which may cause allergic reactions.

It is important to consider the contribution of excipients from all the medicines that the patient is taking.

#### 4.5 Interaction with other medicinal products and other forms of interaction

##### *Influence of other medicinal products on [TB183 trade name]*

Antacids reduce the bioavailability of rifampicin, isoniazid and ethambutol. To avoid this interaction, [TB183 trade name] should be taken at least 1 hour before antacids. Corticosteroids can reduce the plasma levels of isoniazid, by increasing its metabolic and/or renal clearance.

##### *Influence of [TB183 trade name] on other medicinal products*

**Rifampicin** is a very potent inducer of the hepatic and intestinal cytochrome P-450 enzyme system (especially the CYP3A and CYP2C subfamilies). Rifampicin is likely to *accelerate elimination* of co-administered drugs that undergo biotransformation through these metabolic pathways. Rifampicin also induces UDP-glucuronyltransferase, another enzyme involved in the metabolism of several drugs. This can result in subtherapeutic plasma levels of co-administered drugs, with a decreased or even a loss of effect.

These effects approach their maximum after about 10 days of treatment, and gradually return to normal in 2 or more weeks after discontinuation. This must be taken into account when co-administering other drugs. To maintain optimum therapeutic blood levels, doses of drugs metabolised by these enzymes may require adjustment when starting or stopping the concomitant administration of [TB183 trade name].

In vitro, **isoniazid** inhibits CYP2C19 and CYP3A4. Thus it may *reduce elimination* and increase blood levels of drugs mainly eliminated through either of these pathways. However, when given with rifampicin, as when using [TB183 trade name], these effects are likely to be outweighed by the hepatic enzyme induction due to rifampicin. The net effect on drugs affected in opposite ways by rifampicin and isoniazid (such as phenytoin, warfarin and theophylline) is hard to predict and may change over time.

Concurrent use of isoniazid with other hepatotoxic or neurotoxic medicines may increase the hepatotoxicity and neurotoxicity of isoniazid, and should be avoided.

**Ethambutol** has fewer significant pharmacokinetic or pharmacodynamic interactions with other medicines, but particular care may be needed if used with other medicines that also affect visual function.

Thus, mainly due to rifampicin, [TB183 trade name] may interact with a very large number of other drugs, primarily by reducing the exposure to co-administered agents, reducing their efficacy and increasing the risk of therapeutic failure. For many important medicines, no interaction data with rifampicin are available. However, clinically significant reductions in drug exposure may occur.

Whenever co-prescribing any drug together with [TB183 trade name], the possibility of a drug-drug interaction should be considered. The following list of drug interactions with [TB183 trade name] is not exhaustive, but is a selection of interactions of putative importance. The scope of the table is largely based on the WHO Essential Medicines List.

Drugs	Interaction	Recommendations on co-administration
<b>INFECTION</b>		
<i>Antiretrovirals</i>		
<i>Nucleoside analogues</i> <b>Zidovudine</b> / rifampicin	Zidovudine AUC ↓ 47%	The clinical significance of the lowered zidovudine exposure is unknown. Dose modifications of zidovudine in this situation have not been formally evaluated.
<b>Didanosine</b> <b>Emtricitabine</b> <b>Lamivudine</b> <b>Stavudine</b>	No interaction expected	No dose adjustment required.
<b>Tenofovir alafenamide/</b>	Interaction not studied. Co-	Co-administration is not

<b>Drugs</b>	<b>Interaction</b>	<b>Recommendations on co-administration</b>
<b>emtricitabine/</b> <b>rifampicin</b>	administration of rifampicin, a P-gp inducer, may decrease tenofovir alafenamide plasma concentrations, which may result in loss of therapeutic effect and development of resistance.	recommended.
<b>Tenofovir disoproxil / rifampicin</b>	Tenofovir AUC ↓ 13%	No dose adjustment required.
<b>Abacavir / rifampicin</b>	Empirical data are lacking, but rifampicin may decrease abacavir exposure through induction of glucuronidation.	Efficacy of abacavir should be closely monitored in co-treatment.
<i>Non-nucleoside analogues</i> <b>Efavirenz / rifampicin</b>	Efavirenz AUC ↓ 26%	When co-treating with [TB183 trade name], increasing the efavirenz dose to 800 mg daily may be considered
<b>Nevirapine / rifampicin</b>	Nevirapine: AUC ↓ 58%	Concomitant use of [TB183 trade name] and nevirapine is not recommended since appropriate doses of nevirapine when given concomitantly with rifampicin have not been established and the safety of the combination is unknown,
<b>Etravirine / rifampicin</b>	Rifampicin is likely to significantly reduce exposure to etravirine.	Co-treatment of [TB183 trade name] and etravirine should be avoided.
<i>Protease inhibitors</i> <b>Atazanavir / rifampicin</b> <b>Boceprevir</b> <b>Darunavir</b> <b>Fosamprenavir</b> <b>Indinavir</b> <b>Lopinavir</b> <b>Ritonavir</b> <b>Saquinavir</b> <b>Tipranavir</b>	Protease inhibitors exposure will be reduced to subtherapeutic level due to interaction with rifampicin. Increasing doses, or an increase in ritonavir-boosting, have been ineffective or ill-tolerated with a high rate of hepatotoxicity.	[TB183 trade name] must not be co-administered with protease inhibitors for treating HIV or hepatitis C virus infections (see section 4.3).
<i>Others</i> <b>Raltegravir / rifampicin</b>	Raltegravir AUC ↓ 40%	Co-treatment should be avoided. If deemed necessary, consider increasing the raltegravir dose to 600 mg twice daily
<b>Dolutegravir / rifampicin</b>	Dolutegravir AUC ↓ 54%	A dose adjustment of dolutegravir to 50 mg twice daily is recommended when co-administered with [TB183 trade name] in the absence of integrase class resistance. In the presence of integrase class resistance this combination should be avoided.
<b>Elvitegravir/cobicistat/rifampicin</b>	Co-administration has not been studied. Rifampicin is a potent inducer of CYP450 metabolism and may cause significant decrease in the	Co-administration is contraindicated.



Drugs	Interaction	Recommendations on co-administration
	plasma concentration of elvitegravir and cobicistat resulting in loss of therapeutic effect.	
<b>Maraviroc</b> / rifampicin	Maraviroc AUC ↓ 63%	Co-treatment should be avoided. If deemed necessary, the maraviroc dose should be increased to 600 mg twice daily.
<b>Antivirals for hepatitis C infection</b>		
<b>Daclatasvir</b> <b>Elbasvir/Grazoprevir</b> <b>Glecaprevir/Pibrentasvir</b> <b>Ledipasvir/Sofosbuvir</b> <b>Ombitasvir/paritaprevir/ritonavir (with or without dasabuvir)</b> <b>Simeprevir</b> <b>Sofosbuvir (with or without velpatasvir with or without voxilaprevir) /</b>  Rifampicin Isoniazid	<u><b>Rifampicin:</b></u> Co-administration has not been studied but is expected to decrease concentrations of these hepatitis C virus antivirals due to induction of CYP3A4 by rifampicin and hence to reduce their therapeutic effect.  <u><b>Isoniazid:</b></u> Co-administration has not been studied. Patients with current chronic liver disease should be carefully monitored. Severe and sometimes fatal hepatitis associated with isoniazid may develop even after many months of treatment.	Co-administration of [TB183 trade name] with these antivirals is contraindicated (for further details see summary of product characteristics of antivirals for treating hepatitis C virus infection).
<b>Antifungals</b>		
<b>Ketoconazole</b> / rifampicin	Ketoconazole AUC ↓ 80%	Co-administration should be avoided. If deemed necessary, a dose increase of ketoconazole may be required.
<b>Fluconazole</b> / rifampicin	Fluconazole AUC ↓ 23%	Monitor therapeutic effect. An increased dose of fluconazole may be required.
<b>Itraconazole</b> / rifampicin	Itraconazole AUC ↓ 64–88%	Co-administration should be avoided.
<b>Voriconazole</b> / rifampicin	Voriconazole AUC ↓ 96%	Co-administration is contraindicated. If necessary, rifabutin should be substituted for rifampicin.
<b>Antibacterials/tuberculosis medicines</b>		
<b>Clarithromycin</b> / rifampicin	Clarithromycin mean serum concentration ↓ 85%. 14-OH clarithromycin levels unchanged.	Co-administration should be avoided.
<b>Chloramphenicol</b> / rifampicin	Case reports indicate 60–80% reduction of chloramphenicol exposure.	Co-administration should be avoided.

<b>Drugs</b>	<b>Interaction</b>	<b>Recommendations on co-administration</b>
<b>Ciprofloxacin</b> / rifampicin	No significant interaction	No dose adjustment required.
<b>Doxycycline</b> / rifampicin	Doxycycline AUC ↓ 50–60%	If co-treatment is considered necessary, the dose of doxycycline should be doubled.
<b>Metronidazole</b> / rifampicin	Metronidazole AUC i.v. ↓ 33%	The clinical relevance of the interaction is unknown. Dose adjustment is not routinely recommended. Efficacy should be monitored.
<b>Sulfamethoxazole</b> / rifampicin	Sulfamethoxazole AUC ↓ 23%	Interaction probably not clinically significant. Efficacy of sulfamethoxazole should be monitored.
<b>Trimethoprim</b> / rifampicin	Trimethoprim AUC ↓ 47%	A dose increase of trimethoprim may be required. Efficacy should be monitored.
<b>Ethionamide</b> / rifampicin		Rifampicin and ethionamide should not be co-administered, due to an increased risk of hepatotoxicity.
<b>Antimalarials</b>		
<b>Chloroquine</b> / rifampicin		Empirical data are not available. Since chloroquine undergoes polymorphic hepatic metabolism, lower levels are likely during rifampicin co-therapy. Co-administration should be avoided.
<b>Atovaquone</b> / rifampicin	Atovaquone AUC ↓ 50% Rifampicin AUC ↑ 30%	Co-administration should be avoided.
<b>Mefloquine</b> / rifampicin	Mefloquine AUC ↓ 68%	Co-administration should be avoided.
<b>Amodiaquine</b> / rifampicin	Empirical data are not available. Since amodiaquine undergoes hepatic metabolism, it is likely that clearance is increased when co-treating with rifampicin.	Co-administration should be avoided.
<b>Quinine</b> / rifampicin	Quinine AUC ↓ ≈ 80%. This has been associated with significantly higher recrudescence rates.	Co-administration should be avoided. If co-administration is deemed necessary, an increased dose of quinine should be considered.
<b>Lumefantrine</b> / rifampicin	Lumefantrine AUC ↓ 68%	Co-administration should be avoided.
<b>Artemisinin and its derivatives</b> / rifampicin	Artemether AUC ↓ 89% Dihydroartemisinin AUC ↓ 85%	Co-administration should be avoided.

Drugs	Interaction	Recommendations on co-administration
<b>ANALGESICS, ANTIPYRETICS, NON-STEROIDAL ANTI-INFLAMMATORY DRUGS</b>		
<b>Morphine</b> / rifampicin	Morphine AUC p.o ↓ 30%, loss of analgesic effect.	Co-treatment should be avoided. If deemed necessary, efficacy should be monitored and the dose may need to be increased.
<b>Codeine</b> / rifampicin	Plasma levels of morphine, the active metabolite of codeine, are likely to be substantially reduced.	Efficacy should be monitored and codeine dose increased if necessary.
<b>Paracetamol (acetaminophen)</b> / rifampicin  / isoniazid	Rifampicin may increase the glucuronidation of paracetamol and decrease its efficacy.  There may be an increased risk of hepatotoxicity on co-administration, but data are inconclusive. Concurrent use with isoniazid may increase hepatotoxicity.	Co-administration of [TB183 trade name] and paracetamol should be avoided.
<b>Etoricoxib</b> / rifampicin	Rifampicin has been reported to produce a 65% decrease in etoricoxib plasma concentrations when given concomitantly.	Patients should be monitored for possible loss of analgesic effect; however, evidence to support an increase in analgesic dose is lacking.
<b>ANTIPILEPTICS</b>		
<b>Carbamazepine</b> / rifampicin / isoniazid	Rifampicin is expected to decrease serum concentrations of carbamazepine whereas isoniazid may increase them. Neurological side effects and the risk of hepatotoxicity increase when co-treating with carbamazepine.	Co-administration of [TB183 trade name] and carbamazepine should be avoided.
<b>Phenobarbital</b> / rifampicin / isoniazid	Phenobarbital and rifampicin are both strong hepatic enzyme inducers, and each may lower the plasma concentrations of the other. Also, co-treatment with phenobarbital and isoniazid may increase the risk of hepatotoxicity.	Co-administration of [TB183 trade name] and phenobarbital should be undertaken with caution, and the patient monitored for clinical effects and, if possible, plasma drug concentrations.
<b>Phenytoin</b> / rifampicin isoniazid	Phenytoin AUC i.v. ↓ 42% Co-treatment with phenytoin and isoniazid may result in an increased risk of hepatotoxicity.	Co-treatment with phenytoin and [TB183 trade name] should be avoided.

Drugs	Interaction	Recommendations on co-administration
<b>Valproic acid</b> / rifampicin	Interaction studies are lacking. Since valproic acid is eliminated through hepatic metabolism, including glucuronidation, reduced plasma levels of valproic acid are likely with concomitant use.	Co-treatment should be avoided. If deemed necessary, efficacy and, if possible, also plasma concentrations of valproic acid, should be carefully monitored.
<b>Lamotrigine</b> / rifampicin	Lamotrigine AUC ↓ 45%	Co-treatment should be avoided. If deemed necessary, lamotrigine dose should be increased as appropriate.
<b>IMMUNOSUPPRESSANTS</b>		
<b>Ciclosporin</b> / rifampicin	Several studies and case reports have shown substantially increased ciclosporin clearance when co-administered with rifampicin.	Co-administration should be avoided. If deemed necessary, plasma concentrations of ciclosporin should be monitored and doses adapted accordingly (3- to 5-fold increases in ciclosporin dose have been required).
<b>Tacrolimus</b> / rifampicin <b>Sirolimus</b> <b>Everolimus</b>	Tacrolimus AUC i.v. ↓ 35%; AUC p.o ↓ 6870% Sirolimus AUC ↓ 82% Everolimus AUC ↓ 63%	Co-administration of [TB183 trade name] and mTOR inhibitors should be avoided. If deemed necessary, plasma drug concentrations should be monitored, and the dose increased as appropriate.
<b>CARDIOVASCULAR MEDICINES</b>		
<i>ACE inhibitors</i>		
<b>Enalapril</b> / rifampicin	No interaction expected	No dose adjustment required.
<i>Antiarrhythmics</i>		
<b>Lidocaine</b> / rifampicin	Lidocaine CL <sub>i.v.</sub> ↑ 15%	No dose adjustment required
<b>Verapamil</b> / rifampicin	S-verapamil p.o CL/F ↑ 32-fold. With i.v. S-verapamil, CL ↑ 1.3-fold	[TB183 trade name] and oral forms of verapamil should not be co-administered. If i.v. verapamil is given, the therapeutic effect should be carefully monitored; dose adjustment may be required.
<i>Anticoagulants</i>		
<b>Warfarin and other coumarin anticoagulants</b> / rifampicin /isoniazid	Warfarin AUC ↓ 85% Isoniazid may inhibit hepatic metabolism of warfarin.	Monitor closely and adjust warfarin dose as needed and reduce dose after withdrawing rifampicin treatment.
<i>Beta blockers</i>		
<b>Atenolol</b> / rifampicin	Atenolol AUC ↓ 19%	No dose adjustment required.
<i>Calcium-channel blockers</i>		
<b>Amlodipine</b> / rifampicin	Amlodipine is metabolised by CYP3A; lower exposure of amlodipine and potentially other calcium- channel blockers is expected when co-treating with rifampicin.	Efficacy should be monitored.

Drugs	Interaction	Recommendations on co-administration
<b>Cardiac glycosides</b>		
<b>Digoxin</b> / rifampicin	AUC p.o ↓ 30%	When co-administering [TB183 trade name] with digoxin, the efficacy and plasma concentration of digoxin should be monitored. A dose increase may be required.
<b>Statins</b>		
<b>Simvastatin</b> / rifampicin	Simvastatin AUC ↓ 87% Simvastatin acid AUC ↓ 93%	Co-administration is not recommended.
<b>Atorvastatin</b> / rifampicin	Atorvastatin AUC ↓ 80%	Co-administration is not recommended
<b>GASTROINTESTINAL MEDICINES</b>		
<b>Ranitidine</b> / rifampicin	Ranitidine AUC ↓ 52%	Efficacy should be monitored, and ranitidine dose increased if necessary.
<b>Antacids</b> / isoniazid / rifampicin	Antacids may reduce the bioavailability of rifampicin, isoniazid and ethambutol, in the former case by up to a third.  Aluminium hydroxide impairs the absorption of isoniazid.	Acid-suppressing drugs or antacids that do not contain aluminium hydroxide should be used if co-treatment with [TB183 trade name] is necessary.  [TB183 trade name] should be taken at least 1 hour before the antacid.
<b>PSYCHOTHERAPEUTIC MEDICINES</b>		
<b>Anxiolytics and hypnotics</b>		
<b>Diazepam</b> / rifampicin / isoniazid <b>Midazolam</b> <b>Triazolam</b> <b>Alprazolam</b> <b>Nitrazepam</b>	Diazepam AUC ↓ > 70% Midazolam AUC ↓ 98% Triazolam AUC ↓ 95% Alprazolam AUC ↓ 88% Reduced nitrazepam through concentrations, increased clearance.	Co-treatment is not recommended. Benzodiazepine withdrawal may occur in dependent individuals.
<b>Zolpidem</b> / rifampicin <b>Zopiclone</b> / rifampicin	Zolpidem AUC ↓ 73% Zopiclone AUC ↓ 82%	Co-administration should be avoided.
<b>Antipsychotics</b>		
<b>Chlorpromazine</b> / rifampicin / isoniazid	Rifampicin may reduce chlorpromazine exposure. Also, concomitant use of chlorpromazine with isoniazid may impair the metabolism of isoniazid.	Co-administration should be avoided. If considered necessary, patients should be carefully monitored for isoniazid toxicity.
<b>Haloperidol</b> / rifampicin <b>Clozapine</b>	Haloperidol clearance is substantially increased by rifampicin; theoretical considerations imply that same applies to clozapine.	If co-treatment of [TB183 trade name] with haloperidol or clozapine is deemed necessary, monitor clinical efficacy. A dose increase may be required.

<b>Drugs</b>	<b>Interaction</b>	<b>Recommendations on co-administration</b>
<b><i>Tricyclic antidepressants</i></b>		
<b>Amitriptyline</b> / rifampicin <b>Nortriptyline</b>	Case reports (supported by theoretical considerations) suggest that rifampicin considerably increases clearance of tricyclic antidepressants.	Co-treatment should be avoided. If necessary, monitor for clinical response, side effects, and, if possible, plasma concentrations.
<b>HORMONES; OTHER ENDOCRINE MEDICINES AND CONTRACEPTIVES</b>		
<b><i>Corticosteroids</i></b>		
<b>Prednisolone</b> <b>Other systemically administered corticosteroids</b> / rifampicin	Prednisolone AUC ↓ 66%  Also for other corticosteroids, exposure is likely to be substantially decreased when co-treating with rifampicin.	Co-administration of [TB183 trade name] with corticosteroids should be avoided. If deemed necessary, the clinical status of the patient should be carefully monitored, and corticosteroid doses adjusted as needed.
<b><i>Antidiabetics</i></b>		
<b>Glibenclamide</b> / rifampicin <b>Glimepiride</b> <b>Repaglinide</b>	Glibenclamide AUC ↓ 39% Glimepiride AUC ↓ 34% Repaglinide AUC ↓ 57%	Blood glucose levels should be closely monitored. A dose increase of diabetes medication may be required.
<b>Insulin</b>	No interaction expected.	No dose adjustment required.
<b><i>Thyroid hormones</i></b>		
<b>Levothyroxine</b> / rifampicin	Case reports indicate that rifampicin may decrease the effect of levothyroxine.	TSH levels should be monitored.
<b><i>Hormonal contraceptives</i></b>		
<b>Ethinylestradiol</b> / rifampicin	Ethinylestradiol AUC ↓ 66%	Co-administration with [TB183 trade name] may be associated with decreased contraceptive efficacy. Barrier or other non-hormonal methods of contraception should be used.
<b>Norethisterone (norethindrone)</b> / rifampicin	Norethisterone AUC ↓ 51%	Co-administration with [TB183 trade name] may be associated with decreased contraceptive efficacy. Barrier or other non-hormonal methods of contraception should be used.
<b>OTHERS</b>		
<b>Disulfiram</b> / isoniazid	Concurrent use of disulfiram together with isoniazid may increase incidence of adverse effects on the central nervous system.	Dose reduction or discontinuation of disulfiram may be necessary during therapy with [TB183 trade name].

Drugs	Interaction	Recommendations on co-administration
<b>Enflurane</b> / isoniazid	Isoniazid may increase the formation of the potentially nephrotoxic inorganic fluoride metabolite of enflurane.	Co-administration of [TB183 trade name] with enflurane should be avoided.
<b>Methadone</b> / rifampicin	Methadone AUC ↓ 33-66%	Patients should be monitored for possible withdrawal effects, and methadone dose increased as appropriate (up to 2-3 fold)..
<b>Praziquantel</b> / rifampicin	Praziquantel AUC ↓ 80-99%	Co-treatment with [TB183 trade name] should be avoided.
<b>Theophylline</b> / isoniazid / rifampicin	Isoniazid may increase the serum concentration of theophylline and rifampicin may increase it. The effects of combination are unknown.	Theophylline dose adjustment may be needed.

### ***Interactions with food***

Isoniazid is an inhibitor of monoamine oxidase (MAO) and diamine oxidase (DAO), which can reduce tyramine and histamine metabolism, causing symptoms such as headache, sweating, palpitations, flushing, and hypotension. Patients should therefore be advised against ingesting foods rich in tyramine and/or histamine, such as cured meat, some cheeses (e.g. matured cheeses), and some fish (e.g. tuna, mackerel, salmon).

Concurrent daily use of alcohol may result in an increased incidence of isoniazid-induced hepatotoxicity (see section 4.4). Patients should therefore be strongly advised to avoid alcoholic beverages. Wine and beer may also contain tyramine and so cause adverse effects due to MAO inhibition.

### ***Interactions with diagnostic tests***

Rifampicin can delay the biliary excretion of contrast media during gallbladder radiographic examination.

Microbiological methods used to determinate folic acid and cyanocobalamin (vitamin B<sub>12</sub>) plasma concentrations cannot be used during rifampicin treatment as rifampicin is in competition with bilirubin and BSP. To avoid false positive reactions, BSP test should be carried out the morning before rifampicin administration.

## **4.6 Fertility, pregnancy and breastfeeding**

### ***Pregnancy***

There are no well controlled studies with rifampicin in pregnant women. Studies on rifampicin at very high doses in animals have shown reproductive toxicity (see section 5.3). Although rifampicin has been reported to cross the placental barrier and appear in cord blood, the effect of rifampicin, alone or in combination with other antituberculosis drugs, on the human foetus is not known.

Use of rifampicin in the third trimester has been associated with postnatal haemorrhage in the mother and infant. If [TB183 trade name] is used in the last weeks of pregnancy, the mother and neonate should receive vitamin K.

No adverse effects of isoniazid on the fetus have been reported.

Ethambutol crosses the placenta, and may result in foetal plasma concentrations that are approximately 30% of maternal plasma concentrations. Limited clinical data on exposed pregnancies suggest no increase in the rate of foetal malformations in humans. Animal studies have shown a teratogenic potential (see section 5.3).

[TB183 trade name] can be used in pregnancy if the benefits are considered to outweigh the risks. The treatment of TB in pregnant women is the same as for non-pregnant women. As maternal TB increases the risk of vertical transmission of HIV, TB treatment must be started promptly to prevent transmission.

Supplemental pyridoxine (vitamin B<sub>6</sub>) may be recommended in pregnancy (see section 4.4).

#### *Breastfeeding*

Rifampicin, isoniazid and ethambutol appear in human milk. However, concentrations in breast milk are so low that breast-feeding cannot be relied upon for adequate tuberculosis prophylaxis or therapy for nursing infants. No effects on the breastfed newborns/infants are anticipated.

[TB183 trade name] can be used during breast-feeding.

In breast-fed infants whose mothers are taking isoniazid, there is a theoretical risk of vitamin B<sub>6</sub> deficiency, with potential for convulsions and neuropathy. Pyridoxine supplementation should be considered.

#### *Fertility*

No human data on the effect of [TB183 trade name] on fertility are available. Animal studies indicate that co-administration of ethambutol, rifampicin and isoniazid together with pyrazinamide has effects on fertility (see section 5.3).

### **4.7 Effects on ability to drive and use machines**

[TB183 trade name] may have minor to moderate influence on the ability to drive and use machines.

The clinical status of the patient and the adverse reaction profile of [TB183 trade name] should be borne in mind when considering the patient's ability to drive or operate machinery. In particular, undesirable effects of ethambutol, such as confusion, disorientation, hallucinations, dizziness, malaise and visual disturbances (blurred vision, red-green colour blindness, loss of vision), and neurotoxicity associated with isoniazid, may impair the patient's ability to drive or operate machinery.

### **4.8 Undesirable effects**

The most important adverse reactions of [TB183 trade name] are hepatotoxicity, neurotoxicity and effects on vision, due to the components of the fixed-dose combination.

The most important adverse reactions caused by *rifampicin* are hepatotoxicity, particularly cholestatic reactions, and skin reactions. Rifampicin may cause subclinical, unconjugated hyperbilirubinaemia or jaundice without hepatocellular damage, but occasionally causes hepatocellular injury. It can also potentiate the hepatotoxicity of the other anti-tuberculosis medications.

The most important adverse reactions of *isoniazid* are peripheral and central neurotoxic effects, and hepatotoxicity. Severe and sometimes fatal hepatitis due to isoniazid therapy has been reported. The majority of cases have occurred within the first three months of therapy, but hepatotoxicity may also develop after a longer duration of treatment.

The most important adverse reaction of *ethambutol* is retrobulbar neuritis with reduced visual acuity. The frequency depends on the dose and duration of therapy. It has been reported in up to 3% of patients receiving ethambutol 20 mg/kg/day. Typical initial signs include impairment of colour vision (red-green blindness) and constriction of visual field (central or peripheral scotoma). These changes are often reversible if therapy is immediately discontinued when visual disturbances occur (see section 4.4).

#### *Tabulated list of adverse reactions*

In the tables below, ADRs are listed under system organ class (SOC) and ranked by headings of frequency. Within each frequency grouping, adverse reactions are presented in the order of decreasing seriousness, using the following convention: very common ( $\geq 1/10$ ), common ( $\geq 1/100$  to  $< 1/10$ ), uncommon ( $\geq 1/1000$  to  $< 1/100$ ), rare ( $\geq 1/10\ 000$  to  $< 1/1000$ ), very rare ( $< 1/10\ 000$ ), not known (cannot be estimated from the



available data). The table in this section is for adult patients only. Tables have been included for each of the components of the fixed dose combination

### **Undesirable effects of rifampicin daily therapy**

#### **Nervous system disorders**

*Common* Tiredness, drowsiness, headache, light-headedness, dizziness  
*Rare* Ataxia, muscular weakness, myopathy

#### **Psychiatric disorders**

*Rare* Mental confusion, psychosis

#### **Gastrointestinal disorders**

*Common* Anorexia, nausea, abdominal pain, bloatedness  
*Rare* Vomiting, diarrhoea, isolated occurrences of erosive gastritis and pseudomembranous colitis, pancreatitis

#### **Hepatobiliary disorders**

*Common* Asymptomatic increase in liver enzymes  
*Rare* Hepatitis or jaundice, induction of porphyria

#### **Renal and urinary disorders**

*Rare* Elevations of blood urea nitrogen and serum uric acid. Acute renal failure due to haemoglobinuria, haematuria, interstitial nephritis, glomerulonephritis and tubular necrosis have been reported.

#### **Endocrine disorders**

*Not known* Adrenal insufficiency, induction of crisis in Addison patients

#### **Metabolism and nutritional disorders**

*Unknown* Decreased appetite

#### **General disorders**

*Very common* Pyrexia, chills  
*Common* Reddish discoloration of body fluids and secretions such as e.g. urine, sputum, lacrimal fluid, faeces, saliva and sweat; paradoxical drug reaction (appearance of new tuberculosis symptoms despite adherence and absence of resistance).  
*Not known* Collapse, shock, oedema

#### **Blood and lymphatic system disorders**

*Rare* Transient leucopenia, eosinophilia, agranulocytosis.  
Thrombocytopenia and thrombocytopenic purpura occur more frequently with intermittent therapy than with continuous daily treatment, during which they occur only very rarely. When rifampicin administration has been continued after the occurrence of purpura, cerebral haemorrhage and fatalities have been reported.  
Haemolysis, haemolytic anaemia  
*Not known* Disseminated intravascular coagulation has also been reported.

#### **Skin and subcutaneous tissue disorders**

*Common* Flushing, itching with or without skin rash, urticaria  
*Rare* Severe skin reactions such as Stevens-Johnson syndrome and generalised hypersensitivity reactions, e.g. exfoliative dermatitis, Lyell syndrome and pemphigoid reactions

#### **Immune System Disorders**

*Not known* Anaphylaxis

#### **Musculoskeletal disorders**

*Not known* Muscle weakness, myopathy, bone pain

#### **Eye disorders**

*Common* Reddening of the eyes, permanent discoloration of soft contact lenses

*Rare* Visual disturbances, exudative conjunctivitis

### **Reproductive system and breast disorders**

*Rare* Menstrual disturbances (in extreme cases, amenorrhoea);

### **Vascular disorders**

*Not known* Shock, flushing, vasculitis, bleeding

### **Investigations**

*Common* Blood bilirubin increased, aspartate aminotransferase increased, alanine aminotransferase increased

[TB183 trade name] should **not** be used for intermittent treatment regimens. In patients taking rifampicin other than on a daily basis or in those resuming treatment after a temporary interruption, an influenza-like syndrome may occur, this being very probably of immunopathological origin. It is characterised by fever, shivering and possibly headache, dizziness and musculoskeletal pain. In rare cases this flu-like syndrome may be followed by thrombocytopenia, purpura, dyspnoea, asthma-like attacks, haemolytic anaemia, shock and acute renal failure. These serious complications may, however, also set in suddenly without preceding flu-like syndrome, mainly when treatment is resumed after a temporary interruption or when rifampicin is given only once a week in high doses ( $\geq 25$  mg/kg). When rifampicin is given in lower doses (600 mg) 2–3 times a week, the syndrome is less common, the incidence then being comparable to that observed during daily medication.

## **Undesirable effects of isoniazid**

### **Nervous system disorders**

*Very common* Peripheral neuropathy, usually preceded by paraesthesia of the feet and hands. The frequency depends on the dose and on predisposing conditions such as malnutrition, alcoholism or diabetes. It has been reported in 3.5 to 17% of patients treated with isoniazid. Concomitant pyridoxine administration largely reduces this risk (see section 4.4).

*Uncommon* Seizures, toxic encephalopathy

*Not known* Polyneuritis, presenting as muscle weakness, loss of tendon reflexes  
Hyperreflexia may be troublesome with doses of 10 mg/kg

### **Psychiatric disorders**

*Uncommon* Memory impairment, toxic psychosis

*Not known* Elevated mood, psychotic disorder  
Although isoniazid usually has a mood-elevating effect, mental disturbances, ranging from minor personality changes to major mental derangement have been reported; these are usually reversed on withdrawal of the drug

### **Gastrointestinal disorders**

*Not known* nausea, vomiting, anorexia, dry mouth, epigastric distress, constipation, pancreatitis acute

### **Hepatobiliary disorders**

*Very common* Transient elevation of serum transaminases

*Uncommon* Hepatitis

*Not known* Acute hepatic failure, liver injury, jaundice

The risk of these undesirable effects increases with age, especially over the age of 35; it may be serious and sometimes fatal with the development of necrosis.

### **Renal and urinary disorders**

*Not known* Dysuria

### **Metabolic and nutritional disorders**

*Not known* Hyperglycaemia, metabolic acidosis, pellagra, pyridoxine deficiency, nicotinic acid deficiency  
Nicotinic acid deficiency may be related to isoniazid-induced pyridoxine deficiency which affects the conversion of tryptophan to nicotinic acid.

### **General disorders**

*Not known* Pyrexia

### **Respiratory, thoracic and mediastinal disorders**

*Not known* Pneumonitis (allergic), interstitial lung disease

### **Blood and lymphatic system disorders**

*Not known* Anaemia (haemolytic, sideroblastic, or aplastic), thrombocytopenia, leucopenia (allergic), neutropenia with eosinophilia, agranulocytosis, lymphadenopathy

### **Skin and subcutaneous tissue disorders**

*Rare* Toxic epidermal necrolysis, eosinophilia systemic symptoms

*Not known* Erythema multiforme, Stevens-Johnson syndrome, exfoliative dermatitis, pemphigus, rash, acne

### **Immune System Disorders**

*Not known* Anaphylactic reactions

### **Musculoskeletal disorders**

*Not known* Arthritis, systemic lupus erythematosus, lupus-like syndrome, rheumatic syndrome

### **Eye disorders**

*Uncommon* Optic atrophy or neuritis

### **Ear and labyrinth disorders**

*Not known* Deafness, tinnitus, vertigo

These have been reported in patients with end-stage renal impairment

### **Reproductive system and breast disorders**

*Not known* Gynaecomastia

### **Vascular disorders**

*Not known* Vasculitis

### **Investigations**

*Not known* Anti-nuclear bodies

### **Miscellaneous**

Withdrawal symptoms, which may occur on cessation of treatment, include headache, insomnia, excessive dreaming, irritability and nervousness.

## **Undesirable effects of ethambutol**

### **Nervous system disorders**

*Rare* Peripheral neuritis, peripheral neuropathy, paraesthesia (especially in the extremities), numbness

*Very rare* Disorientation, dizziness, headache

### **Psychiatric disorders**

*Very rare* Mental confusion and hallucination

### **Gastrointestinal disorders**

*Not known* Nausea, vomiting, anorexia, flatulence, abdominal pain, diarrhoea

### **Hepatobiliary disorders**

*Very rare* Hepatic failure

*Not known* Hepatitis, jaundice, increase in liver enzymes

### **Renal and urinary disorders**

*Very rare* Nephrotoxicity including interstitial nephritis

### **Eye disorders**

*Uncommon* Optic neuritis (decreased visual acuity, loss of vision, scotoma, colour blindness, visual disturbance, visual field defect, eye pain)

### **Blood and lymphatic systems disorders**

*Rare* Thrombocytopenia,  
*Very rare* Leucopenia, neutropenia

### **Respiratory, thoracic and mediastinal disorders**

*Very rare* Pneumonitis, pulmonary infiltrates, with or without eosinophilia

### **Metabolism and nutrition disorders**

*Uncommon* Hyperuricaemia  
*Very rare* Gout

### **Immune system disorders**

*Very rare* Hypersensitivity, anaphylactoid reactions (see also “Skin and subcutaneous tissue disorders”)

### **Skin and subcutaneous tissue disorders**

*Rare* Rash, pruritus, urticaria  
*Very rare* Photosensitive lichenoid eruptions, bullous dermatitis, Stevens-Johnson syndrome, epidermal necrolysis

### **Musculoskeletal and connective tissue disorders**

*Very rare* Joint pains

### ***Reporting of suspected adverse reactions***

Health care providers are asked to report adverse reactions that may be linked to a medicine, to the marketing authorisation holder, or, if available, to the national reporting system. Reports of suspected adverse reactions to a medicine are important for the monitoring of the medicine’s benefits and risks.

## **4.9 Overdose**

### ***Rifampicin***

Nausea, vomiting, abdominal pain, pruritus, headache and increasing lethargy will probably occur within a short time after acute ingestion; unconsciousness may occur when there is severe hepatic disease. Transient increases in liver enzymes and/or bilirubin may occur. Brownish-red or orange colouration of the skin, urine, sweat, saliva, tears and faeces will occur, and its intensity is proportional to the amount ingested. Facial or periorbital oedema has also been reported in children. Hypotension, sinus tachycardia, ventricular arrhythmias, seizures and cardiac arrest were reported in some fatal cases.

The minimum acute lethal or toxic dose is not well established. However, nonfatal acute overdoses in adults have been reported with doses ranging from 9 to 12 g rifampicin. Fatal acute overdoses in adults have been reported with doses ranging from 14 to 60 g. Alcohol or a history of alcohol abuse was involved in some of the fatal and nonfatal reports.

Nonfatal overdoses of 100 mg/kg for one to two doses have been reported in paediatric patients aged 1 to 4 years.

### ***Management***

Intensive supportive measures should be instituted and individual symptoms treated as they arise. The instillation of activated charcoal slurry into the stomach shortly after overdose may help absorb any remaining drug from the gastrointestinal tract. Antiemetic medication may be required to control severe nausea and vomiting. Active diuresis (with measured intake and output) will help promote excretion of the drug. Haemodialysis may be of value in some patients

### ***Isoniazid***

Typical symptoms are seizures and metabolic acidosis, ketonuria, hyperglycaemia. In addition, there may be periorbital myoclonus, dizziness, tinnitus, tremor, hyperreflexia, paraesthesia, hallucinations, impaired consciousness, respiratory depression, apnoea, tachycardia, arrhythmias, hypotension, nausea, vomiting, fever, rhabdomyolysis, disseminated intravascular coagulation, hyperglycaemia, hyperkalaemia and liver involvement.

Doses of isoniazid exceeding 10 mg/kg may adversely affect the nervous system, e.g. in the form of peripheral neuropathy, and thus impair the patient's ability to drive or operate machinery.

Isoniazid toxicity is potentiated by alcohol. Lethal dose is thought to be 80–150 mg/kg bodyweight. Administration of 3 g to a 5-year old and 5–7.5 g to adults resulted in extremely severe intoxication. A 5-g dose in a 15-year old resulted in lethal intoxication. A dose of 900 mg in an 8-year old has resulted in moderate intoxication and 2–3 g to a 3-year old resulted in severe intoxication.

### ***Management***

Where considered appropriate, evacuation of the stomach (provided the patient is not experiencing seizures) and administration of activated charcoal can reduce absorption if instituted within a few hours of ingestion. Blood samples must be collected for immediate determination of blood gases, electrolytes, BUN, glucose etc. Subsequently, pyridoxine is given (intravenous bolus on a gram-per-gram basis, equal to the isoniazid dose; if the isoniazid dose is unknown an initial dose of 5 g in adults or 80 mg/kg in children should be considered). Pyridoxine should be diluted to reduce vascular irritation and is administered for 30 minutes via infusion pump or syringe pump. The dose is repeated if necessary.

Intravenous diazepam (in case of seizures not responding to pyridoxine) and haemodialysis may be of value. Further treatment should be supportive, with special attention to monitoring and support of ventilation and correction of metabolic acidosis. There is no specific antidote.

### ***Ethambutol***

Loss of appetite, gastro-intestinal disturbances, fever, headache, dizziness, confusion, hallucinations. Data on ethambutol overdose are scarce.

## **5. PHARMACOLOGICAL PROPERTIES**

### **5.1 Pharmacodynamic properties**

*Pharmacotherapeutic group:* Combinations of drugs for treatment of tuberculosis (ATC code: J04AM).

ATC Code for rifampicin: J04AB02

ATC Code for isoniazid: J04AC01

ATC Code for ethambutol: J04AK02

### **Mechanism of action**

In vitro, rifampicin is bactericidal against a wide range of organisms, including *Mycobacterium tuberculosis*. The mode of action is by inhibition of DNA-dependent RNA polymerase, inhibiting transcription. In tuberculosis rifampicin is bactericidal for both intracellular and extracellular microorganisms. Microbial resistance may occur, and is a result of alterations in the target enzyme (RNA polymerase).

Isoniazid is highly active against *Mycobacterium tuberculosis*. It is bactericidal *in vitro* and *in vivo* against actively dividing tubercle bacilli. Its primary action is to inhibit the synthesis of long chain mycolic acids, which are unique constituents of mycobacterial cell wall. Resistance to isoniazid occurs rapidly if it is used alone in the treatment of mycobacterial disease.

Ethambutol at the recommended doses is a bacteriostatic that acts specifically against tubercle bacilli, also against those resistant to other antimycobacterial agents. It possesses very little sterilizing activity. The mechanism of action is not fully known. It diffuses into mycobacteria and appears to suppress multiplication

by interfering with RNA synthesis. It is effective only against mycobacteria that are actively dividing. When ethambutol has been used alone for treatment of tuberculosis, tubercle bacilli from these patients have developed resistance to ethambutol. No cross-resistance between ethambutol and other antituberculous agents has been reported. Ethambutol delays or reduces the incidence of the emergence of mycobacterial resistance to other antimycobacterial agents when used concurrently.

## 5.2 Pharmacokinetic properties

Absorption characteristics were determined following a single dose of [TB183 trade name] in healthy volunteers.

### Ethambutol

Pharmacokinetic Parameter	Test formulation (T) arithmetic mean $\pm$ SD (* )	Reference (R) arithmetic mean $\pm$ SD (* )
$t_{max}$ (h)	3.06 $\pm$ 0.66	2.94 $\pm$ 0.85
$C_{max}$ ( $\mu$ g/ml)	2.09 $\pm$ 0.81 (1.96)	2.27 $\pm$ 1.04 (2.07)
AUC <sub>0-t</sub> ( $\mu$ g.h/ml)	13.18 $\pm$ 3.82 (12.67)	13.60 $\pm$ 3.73 (13.14)
AUC <sub>0-inf</sub> ( $\mu$ g.h/ml)	14.02 $\pm$ 3.89 (13.53)	14.41 $\pm$ 3.72 (13.99)

\* geometric mean

### Isoniazid

Pharmacokinetic Parameter	Test formulation (T) arithmetic mean $\pm$ SD (* )	Reference (R) arithmetic mean $\pm$ SD (* )
$t_{max}$ (h)	1.18 $\pm$ 0.67	1.33 $\pm$ 0.73
$C_{max}$ ( $\mu$ g/ml)	5.57 $\pm$ 1.56 (5.31)	5.45 $\pm$ 1.54 (5.16)
AUC <sub>0-t</sub> ( $\mu$ g.h/ml)	29.20 $\pm$ 16.44 (23.96)	28.84 $\pm$ 16.09 (23.66)
AUC <sub>0-inf</sub> ( $\mu$ g.h/ml)	30.07 $\pm$ 16.80 (24.77)	29.96 $\pm$ 16.56 (24.65)

\* geometric mean

### Rifampicin

Pharmacokinetic Parameter	Test formulation (T) arithmetic mean $\pm$ SD (* )	Reference (R) arithmetic mean $\pm$ SD (* )
$t_{max}$ (h)	2.27 $\pm$ 0.47	1.89 $\pm$ 0.66
$C_{max}$ ( $\mu$ g/ml)	11.33 $\pm$ 2.54 (11.05)	12.65 $\pm$ 2.61 (12.39)
AUC <sub>0-t</sub> ( $\mu$ g.h/ml)	71.15 $\pm$ 20.51 (68.75)	79.59 $\pm$ 24.84 (76.29)
AUC <sub>0-inf</sub> ( $\mu$ g.h/ml)	83.63 $\pm$ 21.44 (81.20)	92.34 $\pm$ 21.76 (89.97)

\* geometric mean

Pharmacokinetics of Ethambutol hydrochloride/isoniazid/rifampicin

	<b>Rifampicin</b>	<b>Isoniazid</b>	<b>Ethambutol</b>
<b>Absorption</b>			
Absolute bioavailability	90–95%	NA*	NA*
Oral bioavailability	> 90%	> 80%	70–80%
Food effect	No effect on extent of absorption. Rate of absorption is reduced.	Reduced.	None
<b>Distribution</b>			
Volume of distribution (mean)	55 L	43 L	20 L
Plasma protein binding <i>in vitro</i>	60–90%	< 10%	10–40%
Tissue distribution	CSF concentrations are of the same order of magnitude as the unbound concentrations in plasma.  Concentrations in liver, spleen, kidneys and lung tissue are higher than serum concentrations. Penetrates into vaginal and cervical tissue and into cervicovaginal fluid. Passes into the placenta; serum concentration in fetus is about 1/3 of those in mother.	Diffuses readily into all body fluids (cerebrospinal, pleural and ascitic fluids), tissues, organs and excreta (saliva, sputum and faeces). Crosses the placenta and passes into milk.	CSF: Relatively low concentrations distributed to CSF
<b>Metabolism</b>			
	Primarily hepatic, rapidly deacetylated.	Hepatic; primarily acetylated by N-acetyltransferase to N-acetylisoniazid	Hepatic
Active metabolite(s)	25-o-deacetyl rifampicin	Nicotinoyl-NAD adduct	NA*
<b>Elimination</b>			
Elimination half life	3–5 hours Decreases to 2–3 hours after repeated administration	1.2 hours: rapid acetylators 3.5 hours: Slow	3–4 hours

		acetylators	
Mean systemic clearance (Cl/F)	5.7–9.0 L/hour	15.5 L/hour: slow NAT2 genotype 26.1 L/hour: rapid/intermediate NAT2 genotype	41 L/hour
% of dose excreted in urine	30%	75–95%	60–80%
% of dose excreted in faeces	60–65%	< 10%	20%
<b>Pharmacokinetic linearity</b>	Non linear	NA*	NA*
<b>Drug interactions (<i>in vitro</i>)</b>	Rifampicin induces hepatic enzymes	Isoniazid is CYP450 inducer and inhibitor.  Isoniazid is a arylamine n-acetyltransferase 2 substrate and inhibitor	NA*
Transporters	Solute carrier transporters (SLC) ATP Binding Cassette transporters (ABC) P-glycoprotein 1	NA*	NA*
Metabolizing enzymes	CYP450	CYP450: 2C19, 3A4	NA*

\*Information not available

## Special populations

### *Rifampicin*

The half-life of rifampicin has been reported to be longer in patients with liver impairment or biliary obstruction.

The half-life does not differ in patients with renal failure at doses not exceeding 600 mg daily, and consequently, no dosage adjustment is required. The half-life of rifampin at a dose of 720 mg daily has not been established in patients with renal failure. Following a single 900 mg oral dose of rifampin in patients with varying degrees of renal insufficiency, the mean half-life increased from 3.6 hours in healthy adults to 5.0, 7.3, and 11.0 hours in patients with glomerular filtration rates of 30 to 50 mL/min, less than 30 mL/min, and in anuric patients, respectively.

In one study, pediatric patients 6 to 58 months old were given rifampin suspended in simple syrup or as dry powder mixed with applesauce at a dose of 10 mg/kg body weight. Peak serum concentrations of  $10.7 \pm 3.7$  and  $11.5 \pm 5.1$  mcg/mL were obtained 1 hour after preprandial ingestion of the drug suspension and the applesauce mixture, respectively. After the administration of either preparation, the  $t_{1/2}$  of rifampin averaged 2.9 hours. It should be noted that in other studies in pediatric populations, at doses of 10 mg/kg body weight, mean peak serum concentrations of 3.5 mcg/mL to 15 mcg/mL have been reported.

### *Isoniazid*

In slow acetylators with severely impaired renal function, accumulation of isoniazid may occur.



An impaired liver function prolongs the elimination half-life of isoniazid.

#### *Ethambutol*

Half is increased up to 8 hours in cases of renal impairment. Ethambutol is not removed from the blood by haemodialysis.

### **5.3 Preclinical safety data**

#### ***Rifampicin***

After oral administration of 100 mg/kg rifampicin for 6 months in rats, no toxic effects were observed. After chronic administration of 200 mg/kg, swelling and hydropic degeneration of the liver were observed. In monkeys, vomiting, anorexia and weight loss were observed at chronic doses of 105 mg/kg/day. There is limited evidence for the carcinogenicity of rifampicin in mice. The available studies on mutagenicity indicate an absence of a mutagenic effect.

An increased incidence of congenital malformations (principally spina bifida and cleft palate) has been reported in the offspring of mice and rats given rifampicin in a dose of 150–250 mg/kg daily during pregnancy. Defective osteogenesis and embryotoxicity occurred when rifampicin doses up to 20 times the usual daily human dose were used in pregnant rabbits.

Fertility and reproductive performance were not affected by oral administration of rifampicin to male and female rats at doses of up to one-third of the human dose.

#### ***Isoniazid***

Non-clinical data reveal no special hazard for humans at recommended doses based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity and carcinogenic potential.

Treatment of pregnant rats with isoniazid resulted in reduced litter sizes and decreased postnatal growth, development, and cognitive ability in the offspring. Spermatogenesis impairment was observed in treated rats.

#### ***Ethambutol***

Toxicological studies on high prolonged doses produced evidence of myocardial damage and heart failure, and depigmentation of the tapetum lucidum of the eyes in the dog. Degenerative changes in the central nervous system, apparently not dose-related, have also been noted in dogs over a prolonged period. In the rhesus monkey, neurological signs appeared after treatment with high doses given daily over several months. These were correlated with specific serum levels of ethambutol and with definite neuroanatomical changes in the central nervous system.

Conflicting results are available on genotoxicity (negative Ames test, negative in human lymphocyte cell cultures, positive in mouse micronucleus).

Cleft palate, exencephaly and vertebral column abnormalities have been observed with high doses in studies in mice. Studies in rats and rabbits have shown that ethambutol in high doses causes minor abnormalities of the cervical vertebrae, limb reduction defects, hare lip and cleft palate in the offspring. Ethambutol decreases testosterone concentrations, spermatogenesis, and male fertility in high doses in rats when administered over 60 days.

A study in male rats determined that co-administration of four antituberculosis drugs, including ethambutol, rifampicin, isoniazid, and pyrazinamide, produced a range of adverse effects on the testes and in sperm, as well as an increase in pre- and post-implantation embryo lethality.

## 6. PHARMACEUTICAL PARTICULARS

### 6.1 List of excipients

*Tablet core:* Colloidal anhydrous silica,  
crospovidone,  
magnesium stearate,  
microcrystalline cellulose,  
povidone,  
pregelatinised starch  
shellac (bleached).  
purified talc

*Film-coat:* Color Ponceau 4R Aluminium Lake,  
hypromellose,  
polyvinyl alcohol-part hydrolyzed,  
purified talc,  
titanium dioxide.  
lecithin  
xanthum gum

### 6.2 Incompatibilities:

Not applicable.

### 6.3 Shelf life:

Bulk pack (HDPE bottle): 24 months  
Blister pack (Alu-PVDC/PVC): 24 months  
Blister pack (Alu-PVC/PE/PVDC): 36 months  
Strip pack (Alu-Alu): 36 months

### 6.4 Special precautions for storage

Storage for [TB183 trade name] are as per packaging below:

- For Blister Pack: Store in a dry place below 25°C and protect from light.
- For Strip pack: Store in a dry place below 30°C and protect from light.
- For Bulk pack: Store at temperature not exceeding 25°C in a dry place.

Tablets should be stored in the original container. Close the container tightly immediately after taking out tablets.

### 6.5 Nature and contents of container

1000 tablets packed in a triple laminated Al/PET/LDPE bag. The bag is packed in a round, white opaque HDPE bottle, sealed with an aluminium tagger and closed with a polypropylene screw cap.  
Al/PVC/PVDC blister of 10 tablets. Such 3, 10 or 24 blisters per box. Pack sizes: 30 (10x3), 100 (10x10), 240 (10x24).  
Al/PVC/PVDC blister of 28 tablets. Such 3, 10 or 24 blisters per box. Pack sizes: 84 (28x3), 280 (28x10), 672 (28x24).  
Al/PVC/PE/PVDC blister of 10 tablets. Such 3, 10 or 24 blisters per box. Pack sizes: 30 (10x3), 100 (10x10), 240 (10x24).

Al/PVC/PE/PVDC blister of 28 tablets. Such 3, 10 or 24 blisters per box. Pack sizes: 84 (28x3), 280 (28x10), 672 (28x24).

Alu-Alu blister strips. Pack size: 30 (5x6), Pack size:100 (10x10) and Pack size:672 (24x28) tablets

## **6.6 Special precautions for disposal and other handling**

No special requirements.

Any unused product or waste material should be disposed of in accordance with local requirements.

## **7. SUPPLIER**

Macleods Pharmaceuticals Ltd.

304, Atlanta Arcade,

Marol Church Road,

Andheri (East),

Mumbai- 400 059,

India

Tel: +91 22 6676 2800

Fax: +91 22 2821 6599

e-mail: [vijay@macleodsPharma.com](mailto:vijay@macleodsPharma.com)

[sjadhav@macleodspharma.com](mailto:sjadhav@macleodspharma.com)

## **8. WHO REFERENCE NUMBER (WHO Prequalification Programme)**

TB183

## **9. DATE OF PREQUALIFICATION**

22 October 2008

## **10. DATE OF REVISION OF THE TEXT**

January 2023

### ***References***

WHO Guidelines for treatment of drug-susceptible tuberculosis and patient care, 2017 Update

WHO, Geneva, 2003: Treatment of Tuberculosis: Guidelines for national programmes

WHO, Geneva, 2006: Ethambutol efficacy and toxicity: literature review and recommendations for daily and intermittent dosage in children

WHO, Geneva, 2022. WHO consolidated guidelines on tuberculosis, Module 5: management of tuberculosis in children and adolescent. Available at: <https://apps.who.int/iris/rest/bitstreams/1414329/retrieve>

WHO, Geneva, 2022. WHO operational handbook on tuberculosis, Module 5: management of tuberculosis in children and adolescents. Available at: <https://apps.who.int/iris/rest/bitstreams/1414333/retrieve>

ATS, CDC, and IDSA. Treatment of tuberculosis. MMWR 2003; 52 (RR-11): 1-88.

Fixed-dose combination tablets for the treatment of tuberculosis Report of an informal meeting held in Geneva Tuesday, 27 April 1999, World Health Organization Communicable Diseases Cluster 1999

Rimstar SPC. Available at:

<https://www.medicines.org.uk/emc/product/2999/smpc> [accessed 26/11/2019]

WHO Model List of Essential Medicines, 15<sup>th</sup> List March 2007. Available at:

[www.who.int/medicines/publications/essentialmedicines/en/index.html](http://www.who.int/medicines/publications/essentialmedicines/en/index.html).

Stockley's Drug Interactions. Available at: [www.medicinescomplete.com](http://www.medicinescomplete.com).

University of Liverpool HIV drug interactions site: [hiv-druginteractions.org](http://hiv-druginteractions.org)

Schaefer C, Peters P, Miller RK (eds). Drugs During Pregnancy and Lactation: Treatment Options and Risk Assessment, 3<sup>rd</sup> edn. Amsterdam: Academic Press, 2015. Available at: <https://doi.org/10.1016/B978-0-12-408078-2.01001-5>.

Kovalenko VM, Bondarenko LB, Byshovetz TF et al: Pyrazinamide effects on male rat's reproductive function. Toxicol Lett 2005;158(Suppl 1):S123.

Adebayo OA, Adesanoye OA, Abolaji OA, Kehinde AO, Adaramoye OA. First-line antituberculosis drugs disrupt endocrine balance and induce ovarian and uterine oxidative stress in rats. J Basic Clin Physiol Pharmacol. 2018 Mar 28;29(2):131-140. doi: 10.1515/jbcpp-2017-0087. PubMed PMID: 29116933.

Shayakhmetova GM, Bondarenko LB, Voronina AK, Matvienko AV, Kitam V, Kovalenko VM. Repeated administration of ethambutol in therapeutic dose causes testes alteration and spermatogenesis disruption in Wistar rats. Hum Exp Toxicol. 2017; 36(5): 520-533.

Shayakhmetova GM, Bondarenko LB, Kovalenko VM. Damage of testicular cell macromolecules and reproductive capacity of male rats following co-administration of ethambutol, rifampicin, isoniazid and pyrazinamide. Interdisciplinary Toxicology 2012; 5(1): 9-14.

*Detailed information on this medicine is available on the World Health Organization (WHO) website:*  
<https://extranet.who.int/pqweb/medicines>